Scientist or Senior Scientist
Assay Development
Posted on 3/29/2023
Cambridge, MA, USA
Experience Level
Desired Skills
  • PhD plus 0-2 years' research experience or BS/MS plus 6-8 years' relevant research experience
  • Experience with primary human cell culture and cell-based in vitro study design and method optimization
  • Experience in assay development, validation, and implementation to support target candidate validation for pre-GLP research
  • Proficiency in molecular biology skills, including primer design, cloning, PCR, qPCR, RT-qPCR, ddPCR, DNA, and RNA isolation
  • Proficiency in cell culture, including primary cells and flow cytometry
  • Experience developing biomarker/clinical biomarker assays would be highly desirable
  • Ability to work effectively on cross-functional teams with a willingness to roll-up-sleeves to get things done
  • Strong oral, written, and verbal communication skills and flexibility to adapt to a dynamic environment
  • Demonstrated maturity to influence, work independently, and cohesively as a self-aware team player
  • Designing, validating, and running assays to demonstrate Prime Editing dependent phenotypic changes
  • Designing, validating, and running immunological assays to both QC Prime Editing components in vitro and assess immune response in vivo
  • Build assay to quantify amounts of Prime Editor components in different tissues post in vivo delivery
  • Generating, analyzing, and interpreting flow cytometry and other complex data sets
  • Coordinating and working with various other groups in a matrixed environment, as well as external CROs
  • Maintaining detailed documentation of experiments in ELN system
  • Presenting data and findings to internal and external scientific groups
Prime Medicine

51-200 employees

Gene editing biotechnology company
Company Overview
Prime Medicine's mission is to transform the lives of patients with debilitating diseases through the application of our groundbreaking Prime Editing platform and technology. The company uses Prime Editing, a next-generation gene editing approach that they believe can address the genetic cause of disease and potentially provide patients with long-lasting cures.